Clinical Trial Update: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase III clinical trial is evaluating HB0025 plus chemotherapy versus tislelizumab plus chemotherapy as first-line therapy for advanced non-squamous non-smal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HB0025
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. | Conditions: Non Squamous Non-small Cell Lung Cancer | Phase 3 | Status: NOT_YET_RECRUITING